A review of the European LeukemiaNet recommendations for the management of CML. (Q38392676)

2 September 2017

1 reference

title

A review of the European LeukemiaNet recommendations for the management of CML. (English)

1 reference

2 September 2017

1 reference

4

Gianantonio Rosti

1 reference

2 September 2017

2

Fausto Castagnetti

1 reference

2 September 2017

3

Gabriele Gugliotta

1 reference

2 September 2017

1

Michele Baccarani

1 reference

2 September 2017

27 March 2015

1 reference

2 September 2017

1 reference

2 September 2017

94 Suppl 2

1 reference

2 September 2017

S141-7

1 reference

Chronic myeloid leukaemia

2 September 2017

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

How I treat CML blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Harmonization of molecular monitoring of CML therapy in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Standardized definitions of molecular response in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Ponatinib in refractory Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response o

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2322-2

10.1007/S00277-015-2322-2

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference

PubMed ID

25814080